TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion at stage IV or at relapse~* Age ≥ 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Measurable lesion defined by RECIST v1.1~* Chemo-naïve or prior chemotherapies~* Adequate organ function~Exclusion Criteria:~* Prior malignancies~* Active CNS disease~* High-risk for gastrointestinal bleeding~* Significant cardiovascular disease~* Uncontrolled hypertension~* Bleeding diathesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib (Type: EXPERIMENTAL): Pazopanib 800mg po qd until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria which must be verified at the end of first 18-months treatment (Visit 9)~* Having completed the previous 18-month treatment period of the EPAAC trial - NCT00152464~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 30 Months
- Maximum Age: 42 Months
- Healthy Volunteers: f

Study Arms:
- LCTZ-LCTZ (Type: EXPERIMENTAL): Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
- LCTZ-PLC (Type: PLACEBO_COMPARATOR): Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
- PLC-PLC (Type: PLACEBO_COMPARATOR): Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Shift to Everolimus (RAD) Kidney Sparing Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Transplant with 1 to 4 years of follow-up~* GFR between 20 and 60 ml/min (calculated with Colkoroft-Gault formula)~Exclusion Criteria:~* Acute rejection in the previous 6 months~* Contraindications to statin therapy~* Ongoing infection~* Ongoing heart failure~* Myocardial infarction or myocardial revascularization after transplant~* Malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mycophenolate (Type: ACTIVE_COMPARATOR): Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
- Everolimus (Type: ACTIVE_COMPARATOR): Everolimus with cyclosporine trough levels between 40 and 90 ng/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients diagnosed with endometriosis that the doctors have already decided to treat with Zoladex within the last month, before inclusion in this program, according to Romanian approved goserelin 3,6 mg~Exclusion Criteria:~* patients who have a known hypersensitivity to goserelin (Zoladex) or any of its excipients or any other GnRH analogue, pregnancy, according to Romanian approved goserelin 3,6 mg SmPC

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients diagnosed with endometriosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Electro-acupuncture and Assisted Reproductive Technology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing medicated frozen embryo transfer uterine preparation~* Ages between 21-45 years old~* Must be fluent in English~* Must be willing to receive four electro-acupuncture treatments~* Must be willing to provide access to medical records from the fertility clinic~Exclusion Criteria:~* Males~* Subjects involved with fresh IVF cycle~* Subjects with pace maker~* Subjects with history of seizure disorders~* All others who do not meet the inclusion criteria

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Electro-Acupuncture (Type: ACTIVE_COMPARATOR): Group will receive 4 acupuncture treatments over 14 days during hormone treatment
- Control (Type: NO_INTERVENTION): Group will not receive acupuncture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Oral Anticoagulation in Haemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥ 18 years)~* Patient on hemodialysis treatment for at least 1 month~* Patient with a history of, or presenting a new episode of atrial fibrillation (either permanent or paroxysmal).~* Patient with a CHADS2VASC score ≥2~* Patient with high risk of bleeding as defined by (1) HASBLED score ≥3 OR (2) HASBLED ≥ CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c), particularly cerebral or gastrointestinal, OR (4) prior recurrent (\>2) history of falls.~* Patient capable of understanding information about the study and of giving his/her consent~* Patient informed of the preliminary medical exam results~* Patient with healthcare insurance~* Written consent signed~Exclusion Criteria:~* Formal indication to oral anticoagulation beside atrial fibrillation (mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome)~* Life expectancy \< 6 months (e.g., terminal cancer)~* Live donor transplantation scheduled within 6 months~* Pregnancy (β-HCG blood-based assay)or nursing (lactating) women~* Women of child bearing potential, unless they are using an effective method of birth control~* Patient under legal guardianship~* Patients under law protection~* Known hypersensibility to coumadin or indoine derivatives or to any excipients (CI to oral AVK)~* Severe liver failure (CI to oral AVK)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No anticoagulation (Type: EXPERIMENTAL): No oral anticoagulation, and no monitoring of the INR.
- Oral anticoagulation with vitamin K antagonists (Type: ACTIVE_COMPARATOR): VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.~Antiplatelet therapy will be provided only if recent acute coronary syndrome (\< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Status post placement of durable ventricular assist device with stable clinical status for \>30days~* Hemoglobin \>6 g/dL AND \<13 g/dL (men) or \<12 g/dL (women) within last 90 days~* Serum ferritin \<100 ng/mL OR Serum ferritin 100-299 ng/mL with transferrin saturation \<20% within last 90 days~* Able and willing to provide written informed consent~Exclusion Criteria:~* Known hypersensitivity to Ferumoxytol injection or other intravenous iron preparation~* History of anaphylaxis~* Treatment with erythropoiesis stimulating agent or intravenous iron in last 3 months~* Renal failure on hemodialysis~* Respiratory failure on mechanical ventilation~* Disabling Stroke~* Ventricular assist device thrombosis~* Evidence of active gastrointestinal bleeding or other active blood loss~* Hospitalization \<30 days~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol injection treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* unresectable and histological or cytological confirmation of adenocarcinoma of the pancreas and measurable disease by CT scan~* patient has not been previously treated for pancreatic cancer~Exclusion Criteria:~* history of cancer other than pancreatic cancer (excluding resected basal cell skin cancer or curative stage 1 cervical cancer if disease free for 5 years or more)~* previous treatment with chemotherapy for pancreatic cancer~* uncontrolled cardiovascular disease (congestive heart failure, symptoms of coronary artery disease, cardiac arrhythmias)~* suffered from myocardial infarction in preceding 6 months~* poorly controlled medical conditions including: asthma, chronic obstructive pulmonary disease, diabetes, seizure disorders, known brain metastases, hepatic or renal failure~* pregnant or nursing women~* known allergy to gemcitabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OGF & Gemcitabine (Type: EXPERIMENTAL): Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Inpatient colonoscopy~2. Age 18 years and older~3. Able to give consent~4. Split dose colonoscopies for all patients~Exclusion criteria:~1. Unable to give consent~2. Pregnant or lactating women~3. Renal impairment (GFR \<30)~4. Ileus~5. Ascites~6. Toxic megacolon~7. Gastrointestinal obstruction~8. Allergy to study drugs~9. Toxic colitis~10. Not able to split the dose of bowel preparations to be used~11. Contraindication to bowel preparation~12. Risk for aspiration~13. Risk of severe cardiac arrhythmias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Low volume prep (Prepopik) (Type: ACTIVE_COMPARATOR): Low volume prep for colonoscopy (Prepopik)
- Moderate volume prep (Moviprep) (Type: ACTIVE_COMPARATOR): Moderate volume prep for colonoscopy (Moviprep)
- High volume prep (Golytely) (Type: ACTIVE_COMPARATOR): High volume prep for colonoscopy (Golytely)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological Age ≥ 3.0 years and ≤ 9.0 years (girls) or ≤ 10.0 years (boys)~* Pre-pubertal status~* Diagnosis of GHD as documented by two or more GH stimulation test results~* Height SD score ≤ -2.0 at screening~* Weight for Stature ≥ 10th percentile~* IGF-I SD score ≤ -1.0 at screening~* Delayed bone age~Exclusion Criteria:~* Prior treatment with any growth promoting agent~* History of, or current, significant disease~* Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome~* Birth weight and/or birth length less than 5th percentile for gestational age~* A diagnosis of Attention Deficit Hyperactivity Disorder~* Daily use of anti-inflammatory doses of glucocorticoid~* Prior history of leukemia, lymphoma, sarcoma or cancer~* Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening~* Significant spinal abnormalities including scoliosis, kyphosis and spina bifida variants~* Significant abnormality in screening laboratory studies

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2: Somavaratan (VRS-317) (Type: EXPERIMENTAL): Active treatment arm
- Phase 3: Somavaratan (VRS-317) (Type: EXPERIMENTAL): Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented, aggressive and/or intermediate grade and high-grade B cell NHL, CD20 positive.~* Histologic subtypes include follicular large cell, diffuse small cleaved cell, diffuse mixed small and large cell, diffuse large cell, anaplastic large cell, and mantle cell lymphomas.~* NHL must have high-intermediate or high International Prognostic Index (standard IPI) score at diagnosis. Mantle cell NHL is eligible regardless of IPI score.~* Complete or partial response to first-line therapy.~* Treated CNS or meningeal disease, using radiation therapy and/or intrathecal chemotherapy, is allowed. Patients with meningeal disease must have cytologically negative CSF at time of study entry.~* Cumulative total doxorubicin: \<500 mg/m2~* Performance score 0-2~* Patients with a prior malignancy are eligible if they were treated with curative intent and have no evidence of active disease.~* Patients must not be pregnant or nursing.~* Informed Consent~Exclusion Criteria:~* pregnant or nursing

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed 1 of the respective short-term antecedent SPD489 MDD studies and did not experience any clinically significant AEs in the antecedent study that would preclude exposure to SPD489.~Exclusion Criteria:~* Subject has any current co-morbid Axis I or Axis II psychiatric disorder (including a lifetime history of psychosis) which was not present or recognized at entry into the antecedent study or has a concurrent chronic or acute illness or unstable medical condition that may deteriorate that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SPD489 + Antidepressant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Donors must satisfy standards including those set forth by FACT (Foundation for the Accreditation of Cellular Therapy) and the criteria specified in FDA 21 Code of Federal Regulations (CFR) 1271. Specifically, screening for risk factors for communicable disease as well as infectious disease screening by serologic and PCR testing as outlined below. Including testing for IV, Hepatitis B, Hepatitis C, HTLV I and II, CMV, EBV, and toxoplasmosis, westnile virus, syphilis, varicella zoster, and Chagas disease.~* Donors must be typed for HLA-A, B, C, DR and DQ at high resolution.~* Donors accrued at MSKCC must have a hemoglobin value \> 10g/dl~* Donors must be capable of undergoing, at least, a single standard 2 blood volume leukapheresis or a donation of one unit of whole blood~* Donors must weight \>/= 25 kg~Exclusion Criteria:~* HTLV/HIV (+) or Hepatitis B or C positive donors~* Donors who are pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Consenting healthy donor (Type: None): Transplant and healthy HLA typed donors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Motivational Interviewing for Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient presentation consistent with a stroke or TIA~* Patient is a current tobacco user and tobacco use contributed to the stroke~* Resident enrolled in study assigned to Vascular Neurology service during patient admission.~Exclusion Criteria:~* Patient unable or unwilling to follow up in the outpatient stroke clinic after discharge~* Patient has cognitive impairment or aphasia that would preclude meaningful participation in motivational interview (defined as a score of 0 on the National Institute of Health Stroke Scale \[NIHSS\] questions 1 and 9)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Motivational Interview (Type: EXPERIMENTAL): Patients included in the study who are being treated by a resident in the MI intervention group will have a motivational interview during their initial hospitalization.
- Control (Type: NO_INTERVENTION): Patients included in the study who are being treated by a resident in the Control group will not have a motivational interview during their hospitalization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Visual Perception During Emotional States on Subjects With an Intrusive Disorder of the Development

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Asperger syndrome or infantile autism (F84.0 et F84.5, classification CIM10, 1992).~* Total score in the algorithm of ADI and ADOS \> at the threshold required for the diagnosis of disorders(confusions) of the autistic spectre~* Intelligence quotient verbal (IQ) upper to 70 in the various tests psychométriques~* Chronological age from 8 to 12 years~* Written consent signed by the parents and the child~* Affiliation or recipient with the mode of social security.~Exclusion Criteria:~* Consent refusal of the child or parents~* Presence of neurovisual disorder

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Patients (Type: OTHER): Mesure of emotional induction by eye tracking on Patient with Pervasive Developmental Disorders (PDD)
- Healthy volunteers (Type: OTHER): Mesure of emotional induction by eye tracking on People without disorders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues